Clinical Trials Logo

Beta Thalassemia Major clinical trials

View clinical trials related to Beta Thalassemia Major.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06291961 Recruiting - Clinical trials for Beta-Thalassemia Major

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Start date: April 18, 2024
Phase: Phase 1
Study type: Interventional

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-thalassemia major anemia.

NCT ID: NCT04353986 Recruiting - HCV Infection Clinical Trials

PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

Start date: June 11, 2018
Phase: Phase 3
Study type: Interventional

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of sofosbuvir, ledipasvir and sofosbuvir metabolite (GS-331007) in HCV infected children with hematological Disorders. to develop predictive pharmacokinetic model for the 3 moieties in the studied population. In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 400 mg of sofosbuvir and 90 mg of ledipasvir(SOF/LED) orally, once daily with food.

NCT ID: NCT03653338 Recruiting - Sickle Cell Anemia Clinical Trials

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Start date: August 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidentical related donor stem cells, this study will increase the number of patients who can undergo a stem cell transplant for their specified disease. Additionally, using a T-cell depleted approach should reduce the incidence of graft-versus-host disease which would otherwise be increased in a mismatched transplant setting.

NCT ID: NCT02342145 Recruiting - Clinical trials for Beta-Thalassemia Major

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major

Start date: June 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major. The objective was to evaluate the effect and safety of basiliximab for acute graft-versus-host disease.